Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors
BOSTON, April 04, 2023 (GLOBE NEWSWIRE) — Entrada Therapeutics, Inc. (Nasdaq:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of Dr. Bernhardt “Bernie” Zeiher to its Board of Directors, effective immediately. Dr. Zeiher served most recently as the Chief Medical Officer at Astellas Pharma.
Related news for (TRDA)
- Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
- Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
- Entrada Therapeutics Reports First Quarter 2025 Financial Results
- Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
- Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44